Home
About Jiuhua
Development process
Company Culture
Jiuhua Honor
Legal Notices
Product Center
Prescription
OTC
Product Research
Medication Consultation
News
Company News
Academic Events
Special Attention
Special attention
Business Cooperation
New drug introduction
Procurement of Medicinal Materials
Infrastructure Construction
Equipment procurement
Investment Agent
Human Resources
Talent concept
Campus Recruitment
Social Recruitment
Contact Us
Contact Information
Online message
Chinese
English
Efficacy observation of Bairui granule combined with ribavirin in the treatment of seasonal influenza in children_Zhu Mingwu
Objective: To observe the clinical efficacy of Bairui granule combined with ribavirin in the treatment of seasonal influenza in children. Methods: 60 children with seasonal influenza were randomly divided into observation group and There were 30 cases in the control group. The children in the control group were treated with ribavirin aerosol, and the observation group was additionally treated with Bairui granules on the basis of the control group. Time to disappearance of symptoms and efficacy. Results: The total effective rate in the observation group was 96. 67%, the total effective rate of the control group was 86. 67%, there was no significant difference between the two groups ( P > 0. 05); There was a statistically significant difference between the two groups (P < 0.05). The disappearance time of clinical symptoms of fever, throat swelling, cough, headache and general pain in the observation group was longer than that in the observation group. The control group was significantly shortened (P < 0.05 or P < 0.01). Conclusion: Bairui granule combined with ribavirin is effective in treating seasonal influenza in children.
20
2021
/
10
Clinical Observation of Bairui Granules in Adjuvant Treatment of Children with Acute Upper Respiratory Tract Infection_Ma Wenxu
Objective: To observe the clinical efficacy of Bairui Granules in the adjuvant treatment of acute upper respiratory tract infection in children. Methods: 180 children with acute upper respiratory tract infection were randomly divided into two groups. There were 90 cases in the control group and the observation group. On the basis of conventional treatment, the control group was given ribavirin 10 mg·kg - 1 ·d-1 , qd, the observation group was given Bairui Keli on the basis of the control group grain. The clinical efficacy, improvement time of main clinical symptoms and signs, hospital stay and adverse drug reactions were compared between the two groups. Results: Except for the disappearance time of rales, the clinical symptoms of the observation group were The improvement time of physical signs and hospital stay were significantly shorter than those of the control group ( P ＜ 0. 05 ) ; the markedly effective and total effective rates of the observation group were significantly higher than those of the control group ( P ＜ 0. 05 ). Two groups of drugs There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The adjuvant treatment of Bairui Granules in children with acute upper respiratory tract infection can significantly improve the symptoms of children. It has obvious curative effect and is worthy of clinical promotion.
Efficacy observation of Bairui granule in adjuvant treatment of mycoplasma pneumoniae pneumonia in children_Li Yanyan
Objective To observe the therapeutic effect of Bairui Granules in adjuvant treatment of children with Mycoplasma pneumoniae pneumonia. Methods July 2014 to 2015 In July 2009, 100 children with MPP who were admitted to the Department of Pediatrics of the Second Affiliated Hospital of Shenyang Medical College were randomly divided into the observation group and the control group with 50 cases in each group. right The control group was given sequential treatment with erythromycin and azithromycin on the basis of conventional symptomatic treatment, and the observation group was given Bairui Granules orally on the basis of the control group. compare two The total effective rate of clinical treatment, fever reduction time, cough disappearance time, lung rales disappearance time, and adverse reactions in the group were compared. result observation The total effective rate in the treatment group was 94% (47/50), which was significantly higher than 80% (40/50) in the control group, and the difference was statistically significant (P<0.05). Fever in the observation group The time, cough disappearance time and lung rales disappearance time were significantly shorter than those of the control group, and the differences were statistically significant (P<0.05). Differences in the two groups of patients The incidence of adverse reactions was similar, and the difference was not statistically significant (P>0.05). Conclusion The adjuvant treatment of Bairui granule in children with Mycoplasma pneumoniae pneumonia can significantly reduce the incidence of pneumonia in children. Improve clinical efficacy, significantly improve symptoms and signs, the treatment is safe and effective, worthy of clinical promotion.
19
Jiuhua Huayuan won the title of "law abiding and honest enterprise in China's pharmaceutical industry in 2020"
18
Professor Yaoyi, winner of FDA Lifetime Achievement Award, visited our Shenzhen headquarters
15
Ⅰ. The company won the title of "2020 Law-abiding and Integrity Enterprise in China's Pharmaceutical Industry"<br> <br> Ⅱ. The company has won the list of "2020 Chinese National Pharmaceutical Excellent Brand Enterprises"<br> <br> Ⅲ. The planting base of Pleurotus is identified as the "Top Ten Anhui Medicines" Industrial Demonstration Base<br> <br> Ⅳ. The company entered the top 100 Chinese traditional medicine enterprises in 2020<br> <br> Ⅴ.Bairui Granules and Yuye Jinhua Qingre Tablets appeared at the National "Thirteenth Five-Year" Science and Technology Innovation Achievement Exhibition<br> <br> Ⅵ. Baimeixing® Bairui Granules entered the "2021 China Pharmaceutical Brand List"<br> <br>
14
09
2020
Ⅰ. The company was selected as the construction unit of the "Top Ten Anhui Medicines" industrial demonstration bases.<br> <br> Ⅱ. The company was rated as "Provincial Key Leading Enterprise of Agricultural Industrialization".<br> <br> Ⅲ. Ranked in the TOP100 list of Chinese traditional Chinese medicine enterprises in 2019!<br> <br>
2019
Ⅰ. The company was rated as "2018 Chuzhou Environmental Protection and Integrity Enterprise".<br> <br> Ⅱ. Bairui Granules entered the new edition of "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2019 Edition)".<br> <br> Ⅲ. Zhenyuan Tablet has entered the new version of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2019 Edition)".<br> <br>
